Pfizer Inc PFE

$27.54 -0.52 (-1.85%)

Valuation

Market cap
159,937,904,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
P/E (trailing)
9.33
P/E (forward)
9.36
Profit margin
12.42%
Debt to equity
0.70

Trading

Volume
35,531,200
Avg volume
33,794,500
Day's range
$27.44 – $27.99
Shares out
5,699,854,000
Stochastic %K
4%
Beta
0.31
Analysts
Hold
Price target
$30.56

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

smartfellar Nov 20, 3:17 PM
$PFE i guess our market maker has the day off today, lord knows he earned it
0 replies
BarkingPuppy Nov 20, 2:54 PM
$ELTP $WEN $AMC $PFE Run Time for ELTP...... Here we go Roaring Kitty
0 replies
dom04 Nov 20, 2:49 PM
$PFE come on you turtle. Rise from the ashes. You can do it slowmo!
1 replies
SellasGPS24BAT14 Nov 20, 2:44 PM
$ABBV $BMY $JNJ $PFE $SLS 0 FDA approved non toxic Cancer treatments. GPS will be the first off the shelf 0 Toxicity cancer drug ever. ✌️🙏❤️‍🩹
0 replies
F_I_R_E_ Nov 20, 2:42 PM
$PYPL $NKE $PFE will necer recover ATH. For smart asses…. Even including the numbers ok
0 replies
Jwil727 Nov 20, 2:42 PM
$DDS Crazy good dividend of $35 a share announced by Dillards!! That’s some series money.💰💰 $TGT $KO $SHOP $PFE
0 replies
SellasGPS24BAT14 Nov 20, 2:39 PM
$SLS $JNJ $PFE $BMY $ABBV 300 Million cash on hand. Shares are locked up. Negotiation from position of strength with backing from biggest banks on the planet to get the deal done. ✌️🙏❤️‍🩹
0 replies
STOCKPICKERTRADER Nov 20, 2:32 PM
$PFE nice to see - Jefferson Research upgrades Pfizer from HOLD to BUY. INVESTARS ANALYST ACTIONS - PUBLIC Nov-19-2026 12:22 p.m. ET On November 19, 2026 Jefferson Research upgraded Pfizer (PFE) from HOLD to BUY.
0 replies